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A long-standing paradox in the study of T cell antigen recognition is that of the high 
specificity–low affinity T cell receptor (TCR)–major histocompatibility complex peptide 
(MHCp) interaction. The existence of multivalent TCRs could resolve this paradox because 
they can simultaneously improve the avidity observed for monovalent interactions and allow 
for cooperative effects. We have studied the stoichiometry of the TCR by Blue Native–
polyacrylamide gel electrophoresis and found that the TCR exists as a mixture of monovalent 
(
 
        
 
) and multivalent complexes with two or more ligand-binding TCR
 
 
 
/
 
 
 
 subunits. 
The coexistence of monovalent and multivalent complexes was confirmed by electron 
microscopy after label fracture of intact T cells, thus ruling out any possible artifact caused 
by detergent solubilization. We found that although only the multivalent complexes become 
phosphorylated at low antigen doses, both multivalent and monovalent TCRs are phosphorylated 
at higher doses. Thus, the multivalent TCRs could be responsible for sensing low concentrations 
of antigen, whereas the monovalent TCRs could be responsible for dose-response effects at 
high concentrations, conditions in which the multivalent TCRs are saturated. Thus, besides 
resolving TCR stoichiometry, these data can explain how T cells respond to a wide range of 
MHCp concentrations while maintaining high sensitivity.
 
The TCR contains a ligand-binding moiety,
formed by a TCR
 
 
 
/
 
 
 
 (or TCR
 
 
 
/
 
 
 
) het-
erodimer noncovalently bound to the signal-
transducing subunits CD3
 
 
 
, CD3
 
 
 
, CD3
 
 
 
, and
 
 
 
 (CD3
 
 
 
/CD247). The TCR serves a critical
role in the differentiation and activation of T
cells and is therefore a key element in the initia-
tion of the adapted immune response. Existing
models of the changes undergone by the TCR
on MHC peptide (MHCp) binding involve
TCR clustering and conformational changes
(1–3). TCR clustering by multimeric MHCp
would bring individual TCRs into close prox-
imity, enabling transphosphorylation of the re-
ceptors by associated tyrosine kinases. Indeed,
soluble monomeric MHCp is not capable of
activating the TCR in CD4
 
 
 
 T cells, unlike
dimeric or oligomeric MHCp (4–6). Neverthe-
less, monomeric MHCp can activate the TCR
in CD8
 
 
 
 T cells (7), possibly via heteroclustering
of the TCR with CD8.
The cytoplasmic tail of CD3
 
 
 
 undergoes a
ligand-induced conformational change that
results in exposure of a proline-rich sequence
and recruitment of the adaptor Nck (8). How-
ever, with one exception (9), crystallographic
data exclude that one 
 
 
 
/
 
 
 
 heterodimer might
undergo major structural changes on MHCp
engagement (10, 11). It is therefore difficult to
envision how a conformational change can be
transmitted from the 
 
 
 
/
 
 
 
 heterodimer to the
CD3 tails.
The TCR provides T cells with the capacity
to discriminate between subtle changes in the
MHCp (2). Moreover, APCs often express a
10
 
3
 
-fold higher concentration of self-MHCp
than antigenic MHCp, but self-MHCp com-
plexes do not elicit a response. Indeed, it is diffi-
cult to understand how the low affinity for an-
tigenic MHCp can simultaneously lead to the
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high specificity observed (5). Therefore, it is clear that a
deeper understanding of the architecture of the TCR is re-
quired to resolve these fundamental questions.
Studies into TCR stoichiometry have not completely
clarified our understanding. In T cells that simultaneously ex-
press human and murine CD3
 
 
 
, the TCR contains at least
two CD3
 
 
 
 subunits (12, 13); because CD3
 
 
 
 pairs with
CD3
 
 
 
 or CD3
 
 
 
, the TCR might contain one 
 
  
 
 and one
 
  
 
. Furthermore, attempts to demonstrate that more than
one 
 
 
 
/
 
 
 
 heterodimer might be present in the complex,
which is critical to determine whether the interaction with
MHCp is monovalent or multivalent, have led to the formu-
lation of two apparently irreconcilable models. Immunopre-
cipitation from cells expressing two different 
 
 
 
/
 
 
 
 het-
erodimers (14) and the construction of the TCR in an in
vitro translation system (15) have indicated that the TCR is
monovalent (i.e., containing one 
 
 
 
/
 
 
 
). However, immuno-
precipitation, sucrose density centrifugation, and fluorescence
resonance energy transfer between two different TCR
 
 
 
 sub-
units have been used to show that the TCR contains at least
two 
 
 
 
/
 
 
 
 heterodimers (16, 17). Analogy between the TCR
and the B cell antigen receptor (BCR) led to the hypothesis
that the TCR might also be oligovalent (18, 19).
Given the importance of the TCR arrangement for un-
derstanding the TCR triggering mechanisms, we have used
Blue Native (BN)–PAGE to study the TCR under nonde-
naturing conditions. Our results show that monovalent
(
 
        
 
) and multivalent high molecular weight TCR
species coexist in T cells, findings that were confirmed by
immunoelectron microscopy on intact T cells. Finally, we
show that the multivalent TCR endows the T cell with its
acute sensitivity, whereas the monovalent TCR allows the
T cell to show concentration-dependent responses at high
antigen concentrations.
 
RESULTS
The TCR appears as a distinct complex with a 
 
        
 
 
stoichiometry when solubilized in digitonin
 
To distinguish between monovalent and bivalent/multiva-
lent formations of the TCR complex using BN-PAGE (Fig.
1 A), we established gentle purification procedures to isolate
the TCR complex in its native form. A nitro-hydroxy-phe-
nylacetate (NP)–specific single chain (sc) TCR
 
 
 
 protein was
constructed and stably transfected into wild-type Jurkat (Jk)
T cells, as well as into a TCR
 
 
 
-deficient Jk mutant line (31-
13). This scTCR complex can be immobilized on NP col-
umns and eluted with the higher affinity iodo-NP (NIP)
hapten. Furthermore, membrane preparations solubilized in
digitonin were analyzed directly by BN-PAGE. Finally, an
antiphosphotyrosine antibody was used to immunoprecipi-
tate proteins from detergent lysates of pervanadate-stimu-
lated cells, followed by elution of phosphoproteins with
phenylphosphate and dephosphorylation. Purified TCR
complexes isolated from digitonin-solubilized cell lysates by
the above procedures were subjected to BN-PAGE, and im-
munoblotting was performed with an anti-
 
 
 
 antiserum (Fig.
1 B). Because 
 
 
 
 is the last subunit to be added to the TCR
complex during assembly (20, 21), the use of this anti-
 
 
 
 anti-
serum in immunoblotting permits the detection of com-
Figure 1. Digitonin-solubilized TCR has an          stoichiometry. 
(A) Current structural models of the TCR complex. The minimal hexameric 
complex, which comprises one TCR /  dimer (monovalent), and an alter-
native model with two TCR /  dimers (bivalent) are shown. (B) The digitonin-
solubilized TCR complex is of a defined size. TCRs from the sources indicated 
were prepared either by NIP elution from NP-Sepharose columns, from 
membrane fractions, or by phenylphosphate elution from antiphosphoty-
rosine affinity columns. After separation by BN-PAGE, immunoblotting 
was performed with an anti-  serum. As a control, the BCR was run in parallel 
and immunoblotted with an antilight chain serum. The marker protein in this 
and all subsequent BN-PAGEs is ferritin in its 24-mer, 48-mer, and 72-mer 
forms (f1, 440 kD; f2, 880 kD; and f3, 1,320 kD). (C) The digitonin-solubilized 
TCR contains two CD3 dimers. TCRs contained in total membrane fractions 
from human PBMCs (lanes 1–3) or in antiphosphotyrosine immunoprecip-
itates from CH7C17 T cells (lanes 4–6) were incubated with the amounts of 
the anti-CD3 (UCHT1) Fab fragments indicated and resolved by BN-PAGE. 
(D) The digitonin-solubilized complex contains one TCR  subunit. TCRs 
prepared from antiphosphotyrosine immunoprecipitates of human PBMCs 
(lanes 1–3) or CH7C17 cells (lanes 4–5) were incubated with the anti-TCR  
antibodies Jovi1 (lanes 1–3) or Jovi3 (lanes 4–6) and resolved by BN-PAGE. 
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pletely assembled complexes. Irrespective of the method or
the cells used, the TCR appeared as a single band that char-
acteristically migrated near the ferritin f1 marker (Fig. 1 B).
Although the mass of a complex cannot be accurately de-
duced from its mobility in BN-PAGE (19), it is a valid
method to measure relative molecular sizes. Hence, the
complexes containing scTCR
 
 
 
 were larger than wild-type
complexes because of the addition of the sc domains (Fig. 1
B, compare lane 4 with 5). Furthermore, the TCR complex
was smaller than the BCR (lane 10). The use of other anti-
bodies for inmmunoblotting demonstrated that the digito-
nin-solubilized complex contained CD3
 
 
 
 and TCR
 
 
 
/
 
 
 
,
confirming that the complex recognized by the anti-
 
 
 
 antise-
rum is indeed the TCR (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20042155/DC1).
To ascertain the stoichiometry of the digitonin-solubi-
lized TCR complex, we developed a gel shift assay. TCR
complexes from primary human T cells (Fig. 1 C, lanes 1–3)
or the Jk-derived T cell line CH7C17 (lanes 4–6) were in-
cubated with different amounts of the Fab fragment of the
anti-CD3 antibody UCHT1 (specific for 
 
  
 
 and 
 
  
 
 dimers;
reference 22) and subjected to BN-PAGE. The binding of
the Fab fragment to the TCR was reflected by the appear-
ance of two shifted bands indicative of two UCHT1 binding
sites. Thus, we concluded that the digitonin-solubilized
TCR contains two CD3 dimers. In contrast, only one shift
was produced by binding an anti-TCR
 
 
 
 antibody (Fig. 1 D,
lanes 1–3 using PBMCs and lanes 4–6 using CH7C17), indi-
cating that the digitonin-solubilized complex contains one
 
 
 
/
 
 
 
 heterodimer. For the anti-TCR
 
 
 
 
 
shift assay (Fig. 1 D)
we used a whole antibody, thus explaining the reduced mo-
bility of the shifted complex compared with the TCR com-
plex bound to one Fab fragment of the anti-CD3 antibody
(Fig. 1 C). Nevertheless, the use of a Fab fragment of a dif-
Figure 2. The Brij96-solubilized TCR appears in distinct and stable 
high molecular weight complexes. (A) Part of the Brij96-solubilized TCR 
has a low mobility in BN-PAGE. TCRs, prepared from total membranes of 
human PBMCs (lanes 1 and 2) or by antiphosphotyrosine immunoprecipi-
tation from 2B4 and Jk cells (lanes 3 and 4), were solubilized either in 
digitonin or in Brij96 and analyzed by BN-PAGE. (B) The TCR does not 
aggregate in Brij96. Jk cells were lysed, and the TCR was immunoprecipi-
tated with antiphosphotyrosine in the continuous presence of either 
digitonin (lane 1) or Brij96 (lane 2). Alternatively, they were lysed in digi-
tonin, and immunoprecipitation and loading were performed in Brij96 
(lane 3). (C) The TCR does not aggregate during a second BN-PAGE in 
Brij96. TCRs were isolated from Jk by antiphosphotyrosine immunopre-
cipitation and analyzed by two-dimensional BN/BN-PAGE. (D) Other cell 
surface proteins did not appear in high molecular weight complexes 
when the cells were lysed in Brij96. Total membrane fractions of Jk cells 
were solubilized in digitonin or Brij96 and separated by two-dimensional 
BN/SDS-PAGE. Immunoblotting was performed with the antibodies indi-
cated. The arrowheads indicate the LAT spot. (E) The Brij96-extracted TCR 
contains the  / ,  , and CD3 subunits. TCR from Jk.flag  cells was analyzed 
by two-dimensional gel BN/SDS-PAGE. Immunoblotting was performed 
with antibodies to the indicated TCR subunits. (F) The Brij96-solubilized TCR 
is not found associated to cell surface proteins other than the TCR sub-
units. Jk.scTCR  cells were surface iodinated and lysed in the detergent 
indicated. After immunoprecipitation with the anti-CD3 antibody UCHT1, 
TCR complexes were resolved by two-dimensional SDS-PAGE (nonreducing/
reducing) and visualized by autoradiography. 
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ferent anti-TCR
 
 
 
 antibody in another T cell system also re-
sulted in a single shifted band (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20042155/DC1). The
shift in Fig. 1 D, lanes 1–3, was not complete, possibly be-
cause the shifting antibody only recognizes C
 
 
 
1-TCRs, thus
leaving the C
 
 
 
2-TCRs unbound. Collectively, these results
and the use of a battery of other TCR-specific and control
antibodies (unpublished data) allowed us to conclude that
in digitonin the TCR complex has a stoichiometry of
 
        
 
 and is therefore monovalent.
 
The TCR is detected in high molecular weight complexes 
when solubilized in Brij96
 
To investigate whether the detergent used for solubilization
influences the size and stoichiometry of the TCR complex,
we analyzed the TCR in several detergents known to re-
spect the interactions between TCR and CD3 subunits. In
contrast to TCRs solubilized in digitonin, TCRs solubilized
in Brij58, Brij96, Brij97, and Brij98 did not migrate as a dis-
crete band in BN-PAGE (Fig. 2 A and not depicted). In-
deed, only a portion of the TCR complex isolated with
Brij96 had the same mobility as the digitonin-solubilized
monovalent complex (Fig. 2 A); the rest of the TCR was
found in complexes of higher molecular weights. The larger
complexes did not appear to result simply from incomplete
solubilization of membrane proteins because higher and
lower doses of Brij96 did not alter the mobility of the com-
plex (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20042155/DC1). Furthermore, the larger
complexes did not result from artifactual aggregation pro-
voked by Brij96 because the digitonin-solubilized complex
was not aggregated when transferred to Brij96 (Fig. 2 B,
lane 3). Further proof against a possible aggregation effect of
Brij96 was obtained in two-dimensional BN/BN-PAGE in
which the mobility of each molecular species remained
unaltered in the second dimension, thus forming a perfect
diagonal (Fig. 2 C). Most important, when a battery of mem-
brane proteins was analyzed by two-dimensional BN/SDS-
PAGE, the mobility of the other membrane proteins
(CD45, CD59, LAT, and Lck) in Brij96 and digitonin var-
ied little in comparison with the large differences in mobil-
ity observed for the TCR (Fig. 2 D). Therefore, the varying
mobility of the TCR when extracted in Brij96 versus digi-
tonin is rather a specific property of the TCR and not a
general property of the detergent.
When the composition of these high molecular weight
complexes was analyzed, the TCR
 
 
 
, CD3
 
 
 
, and 
 
 
 
 chains
were detected (Fig. 2 E). Although this suggests that their
large size was not caused by the association of 
 
 
 
 with recep-
tors other than the TCR, the possibility remained that when
solubilized in Brij96 the TCR might remain associated to
membrane proteins that are released in digitonin. Two-
dimensional SDS-PAGE was performed on anti-CD3 immu-
noprecipitates obtained from surface 
 
125
 
I-labeled Jk.scTCR
 
 
 
cells. All the TCR subunits were isolated when solubilized
in both detergents, including heterodimers of TCR
 
 
 
 with
endogenous TCR
 
 
 
 and scTCR
 
 
 
 (Fig. 2 F). Indeed, no es-
sential differences could be observed in the 2D profiles of ei-
ther complex. Moreover, we were unable to detect any ad-
ditional proteins in the Brij96-solubilized TCR isolated
from metabolically labeled cells when compared with that
isolated from cells lysed in digitonin (unpublished data).
Therefore, the size heterogeneity of the TCR complex in
Brij96 was not caused by the association of other proteins.
Although non-TCR proteins (e.g., signaling proteins) might
be associated to the low and high molecular weight TCRs in
resting T cells, these associations would be at such low sto-
ichiometric ratios that they could not explain the observed
size heterogeneity.
Figure 3. Presence of a cholesterol-dependent multivalent TCR in 
Brij96 lysates. (A) The Brij96-solubilized TCR contains at least two  /  
heterodimers. Jk.scTCR  cells coexpressing TCR  and scTCR  were lysed 
in digitonin or Brij96 (lanes 2 and 4). scTCR -containing complexes were 
isolated using NP-Sepharose and resolved by nonreducing SDS-PAGE. As a 
control, the same procedure was applied to a mixture of Jk and 31-13.scTCR  
cells (lanes 1 and 3). In addition, the TCR of Brij96-lysed Jk cells was 
immunoprecipitated using an anti-CD3 antibody. Immunoblotting was 
performed using an anti-TCR–V 8 antibody, which only recognizes the 
endogenous TCR  (top). The membrane was reprobed with an anti-TCR–C  
antibody (bottom), which recognizes both the endogenous TCR  and the 
transfected scTCR . (B) The high molecular weight TCR complexes disappear 
on treatment with M CD. 31-13.scTCR  cells were lysed in either digitonin or 
in Brij96 in the presence of the concentrations of M CD indicated, and 
the TCR was purified by NP-Sepharose precipitation.JEM VOL. 202, August 15, 2005 497
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Brij96 extraction, as opposed to digitonin extraction, 
preserves a cholesterol-dependent multivalent TCR
To determine whether the size heterogeneity detected by
BN-PAGE corresponded to the coexistence of different oli-
gomeric forms of the TCR complex, Jk.scTCR  cells were
lysed in either Brij96 or digitonin, and the scTCR -contain-
ing TCR was precipitated with NIP-Sepharose (Fig. 3 A,
lanes 2 and 4). The precipitate was analyzed by immunoblot-
ting with an anti-V 8 antibody that recognizes endogenous
(TCR-V 8) but not transfected (scTCR-V 3) TCR 
chains. The endogenous TCR  coprecipitated with scTCR 
from Brij96 but not from digitonin lysates. Furthermore, en-
dogenous TCR  could not be coprecipitated from Jk and 31-
13.scTCR  cell mixtures (lane 3), thus excluding the possi-
bility that these TCR complexes associated after lysis of the
cells. The presence of scTCR  in all the immunoprecipitates
Figure 4. Monovalent and multivalent TCRs coexist on the intact cell 
surface. (A) Large TCR complexes exist on the T cell surface. 2B4 cells labeled 
after fixation with the anti-CD3 dimer antibody 145-2C11 and 10 nm gold–
protein A are shown at low (left) and high magnification (right). Bars: (left) 2 
 m; (right) 100 nm. Before immunolabeling, cells were incubated with 5 mM 
M CD or left untreated. Photographs were taken after label fracture by trans-
mission electron microscopy and show the immunogold labeling from the 
internal side of the plasma membrane. Closed arrows, multivalent complexes; 
open arrows, monovalent TCRs. (B) The large TCRs are multivalent. Anti-TCR  
immunogold-labeled TCRs from untreated or M CD-treated 2B4 cells are 
shown. Closed arrows, multivalent complexes; open arrows, monovalent TCRs. 
Bar, 60 nm. (C and D) The large TCRs are disassembled by cholesterol extrac-
tion. The total number of clusters of each size in untreated and M CD-treated 
2B4 cells are shown (C). Distribution of gold particles according to the cluster 
size is shown as a percentage of the total number of gold particles (D). Black 
bars, untreated cells; white bars, M CD-treated cells. (E) Multivalent TCRs have 
a propensity to form linear arrays. Various representative individual large TCR 
complexes stained by the 145-2C11 antibody are shown. (F) Multivalent and 
monovalent TCRs are coexpressed in different T cell lines and primary T cells. 
The Jk-derived CH7C17 cell line and human PBMCs were labeled after fixation 
with anti-CD3 dimer antibody OKT3 and 10 nm gold–protein A as in panel A. 
Closed arrows, multivalent complexes; open arrows, monovalent TCRs.MULTIVALENT AND MONOVALENT TCR COMPLEXES | Schamel et al. 498
was confirmed by reprobing the membrane with an anti-C 
antibody that recognizes both TCR  chains (Fig. 3 A). Al-
though these results further support a monovalent stoichiom-
etry for the complex isolated in digitonin, the coprecipitation
of two different TCR s in Brij96 shows that the TCR can
contain at least two  /  heterodimers in this detergent.
The size heterogeneity of the TCR complex in Brij96
could be explained if it comprised a mixture of monovalent,
bivalent, and higher order multivalent TCR structures. Be-
cause digitonin is a cholesterol-solubilizing detergent, it is
possible that the sequestering of cholesterol caused the dis-
ruption of the high multivalent TCR complexes. This in-
deed seems to be the case because incubating the TCRs
isolated from Brij96-solubilized lysates with methyl- -cyclo-
dextrin (M CD), a cholesterol-extracting agent, reduced the
size of the TCR to that of the monovalent complex (Fig. 3
B). This result suggests that cholesterol is required to main-
tain the structure of the multivalent TCR complexes, but
not of the monovalent form.
Multivalent and monovalent TCRs coexist on the plasma 
membrane of intact nonstimulated T cells
To confirm that multivalent TCRs exist at the T cell surface,
fixed nonstimulated 2B4 T cells were immunolabeled with
an anti-CD3 antibody visualized with 10 nm gold–protein
A. In label fracture and transmission electron microscopy, a
mixture of TCR complexes of different size was apparent in
the plasma membrane (Fig. 4, A and E). Indeed, a significant
(P   0.0001) proportion of the TCR complexes was labeled
with more than two gold particles, indicating that at least
these complexes were multivalent (Fig. 4 A, closed arrows).
However, monovalent complexes, labeled with one gold
particle where the bivalent anti-CD3 antibody binds simul-
taneously to the two CD3 dimers of the complex, were also
observed (open arrows). Cholesterol extraction with M CD
disrupted the large complexes favoring the appearance of the
smaller complexes without diminishing the total amount of
TCR on the cell surface (Fig. 4, A and C). This confirms the
data obtained by BN-PAGE (Fig. 3 B) and excludes that the
accumulation of gold particles is caused by antibody aggrega-
tion. The coexistence of multivalent and monovalent TCR
complexes and the cholesterol dependence were also dem-
onstrated in cells labeled with an anti-TCR  antibody (Fig.
4 B). Of note, we often were unable to detect a gap between
two adjacent gold particles (Fig. 4, A, B, E, and F). Consid-
ering the size of these particles (10 nm) and the resolution of
the microscope, one can calculate that the gap must be
smaller than 1 nm, indicating a very close interaction be-
tween the TCR complexes (see Discussion). An estimate of
the distribution of gold particles in isolated TCRs and TCR
clusters indicates that more than half (55%) of the TCR in
untreated 2B4 cells is in the form of multivalent complexes
(Fig. 4, C and D). Interestingly, the large TCR complexes
were not present as unorganized clusters but had a propen-
sity to assemble into linear structures (Fig. 4 E). Linear mul-
tivalent TCR complexes were also detected in CH7C17 and
Figure 5. The monovalent and multivalent TCR complexes are differ-
entially sensitive to antigen stimulation. (A and C) T cells respond differen-
tially over a wide range of antigen concentrations. The HA peptide–specific T 
cell line CH7C17 and the PCC peptide–specific T cell hybridoma 2B4 were 
stimulated for 24 h with varying concentrations of peptide loaded onto either 
DAP-DR1 or DCEK APCs. Surface staining of the T cells with anti-CD69 anti-
bodies was measured using a flow cytometer and the percentage of positive 
cells is depicted in semilogarithmic scale. Values are mean   SD. (B and D) At 
low antigen doses, only multivalent TCRs become tyrosine phosphorylated. 
CH7C17 and 2B4 cells were antigen stimulated for 5 min as in A and C or 
stimulated with pervanadate. Cells were lysed in Brij96, and phosphorylated 
TCRs were affinity purifed with immobilized antiphosphotyrosine antibody 
and resolved by two-dimensional BN/reducing SDS-PAGE. Immunoblotting 
was performed using an antiphosphotyrosine antibody (B) or anti-  (D). The 
position of phosphorylated   (p- ) is indicated.JEM VOL. 202, August 15, 2005 499
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in primary human T cells (Fig. 4 F) in which  45% of the
TCR was found as multivalent complexes (unpublished
data). These results are therefore in agreement with the BN-
PAGE and coimmunoprecipitation data and show that TCR
monovalent and multivalent complexes are coexpressed on
the surface of intact T cells.
Only multivalent TCR complexes are tyrosine phosphorylated 
when stimulated with low concentrations of antigen
There is a large body of evidence demonstrating that T cells
respond to a wide range of antigen concentrations (6, 23–
25). Moreover, although T cells can respond to a few
MHCp molecules, they still show increasing responses to
concentrations that exceed by 5 or more orders of magni-
tude the minimal effective concentration (26, 27). To deter-
mine whether the multivalent and monovalent TCRs are
differentially involved in the response to low and high anti-
gen concentrations, we used the CH7C17 Jk T cell line
(specific for the hemagglutinin HA307-319 peptide in com-
bination with HLA-DR1; reference 28). When these cells
were incubated with HA peptide–loaded DR1-expressing
cells, the activation marker CD69 was up-regulated in a
dose-dependent manner over a concentration range of
nearly four orders of magnitude (Fig. 5 A). We stimulated
CH7C17 cells with different concentrations of HA peptide
loaded onto the presenting cells and monitored the appear-
ance of the 23-kD phosphorylated   form, indicative of ac-
tive TCRs, by two-dimensional BN/SDS-PAGE followed
by antiphosphotyrosine immunoblotting (Fig. 5 B). Clearly,
at low antigen doses (4–10  M) only the multivalent com-
plexes were phosphorylated, whereas the monovalent com-
plexes became phosphorylated at higher concentrations (40–
100   M). In contrast, both types of TCR complexes,
monovalent and multivalent, were phosphorylated after
pharmacological stimulation with pervanadate (Fig. 5 B).
Therefore, at low concentrations of antigen, only the  
chains present in multivalent TCRs became phosphorylated,
whereas the monovalent TCRs required higher antigen
concentrations, a situation in which the multivalent com-
plexes might already be saturated.
This type of experiment was repeated using 2B4 as re-
sponding T cells and DCEK primed with pigeon cytochrome
c (PCC) peptide as APCs. 2B4 cells already responded by in-
creasing CD69 expression at a concentration as low as 5 pM
and still showed dose-dependent responses at concentrations
of 0.5–30  M (i.e., six to seven orders of magnitude higher;
Fig. 5 C). Our biochemical approach was not sensitive
enough to detect induced tyrosine phosphorylation of   at
concentrations  1.5  M. At this concentration of antigen,
we could detect tyrosine phosphorylation of the multivalent
TCRs and also some phosphorylation of the monovalent
TCR (Fig. 5 D). However, a 20-fold increase in antigen
concentration (30  M) led to increased tyrosine phosphory-
lation of the monovalent but not the multivalent TCRs.
These results confirm the CH7C17 data by showing that at
low concentrations of antigen, the multivalent TCRs are al-
ready saturated, whereas the monovalent TCR is still increas-
ingly phosphorylated at increasing antigen concentrations.
DISCUSSION
We show that multivalent and monovalent forms of the
TCR coexist in the T cell membrane. Other studies have
failed to detect the multivalent complexes (14, 15), probably
because they relied on the use of digitonin, a detergent that
disassembles the multivalent TCR. Furthermore, although
one of these studies (15) is limited to an in vitro translation
system, we have studied TCR stoichiometry in both digito-
nin and Brij96 lysates of T cells as well as in intact T cells.
Thus, the picture that emerges from our data is that there is
not a single stoichiometry of the TCR but a combination of
monovalent and multivalent complexes, the latter being
formed by a heterogenous combination of dimers, trimers, et
cetera, including TCR complexes with  20 TCR units.
Using a novel method, we demonstrate that the TCR has a
stoichiometry of          when extracted from T cells
in digitonin, possessing only one ligand-binding moiety
(monovalent TCR). Although this is in agreement with the
stoichiometry found in the in vitro translation system (15),
the stoichiometry of the minimal TCR unit (i.e., in the ab-
sence of digitonin) is still unknown. The multivalent TCR
complexes identified in Brij96 do not migrate as discrete
bands in BN-PAGE, raising the concern that they are arti-
facts produced by the detergent. We have, however, ex-
cluded this possibility because Brij96 did not cause the ag-
gregation of TCRs, in agreement with a recent study in
which Brij98 did not produce a mixing of distinct mem-
brane microdomains (29). Furthermore, our study shows
that other membrane proteins extracted in Brij96 are not
present in high molecular weight complexes. Finally, and
most important, small and large TCR complexes were seen
to coexist on the cell surface of nonstimulated immunogold-
labeled T cells, reflecting the monovalent and multivalent
stoichiometries. Interestingly, a variety of multivalent TCRs
appear to be generated, ranging from complexes that com-
prise only a few CD3 and TCR /  dimers to huge com-
plexes consisting of  20 CD3 and TCR /  dimers. Thus,
the different molecular weights found in BN-PAGE possibly
reflect the distinct stoichiometries found by electron micros-
copy. Because proteins in general did not run as sharp bands
when Brij96 is present during BN-PAGE separation, the
mixture of molecularly distinct TCR complexes overlap,
producing a continuous smeary band.
The multivalent complexes were predominantly found as
linear structures (Fig. 4), possibly indicating that the large
TCR multimers are assembled rather than randomly aggre-
gated. The distance between two 10-nm gold particles is of-
ten smaller than 1 nm (Fig. 4). Because the widths of
TCR /  and the CD3 dimers are in the range of 50 Å, the
maximal width of a monovalent TCR complex is 150 Å
(30), larger than the 10-nm gold particles. Indeed, our pre-
liminary electron microscopy data on purified TCR com-
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slightly larger than 100 Å (unpublished data). Therefore, the
proximity between gold particles in the electron microscopy
experiments strongly suggests the presence of protein–protein
interactions within the multivalent complexes. Clearly, this
hypothesis will have to be addressed experimentally. The or-
ganization of the multivalent complexes in linear arrays could
indicate the existence of a monospecific interaction between
TCRs (i.e., between one subunit of a monomeric complex
and another subunit of the next complex). Indeed, in an ear-
lier study we suggested the possible existence of linear arrays
of the TCR maintained by V –V  interactions (16). How-
ever, other interactions are possible, even if the minimal
TCR complex is indeed the monovalent complex (e.g., a
CD3 –CD3 , a CD3 –CD3 , or a  2– 2 interaction).
Similarly, the proximity between two TCR  subunits
has been shown using fluorescence resonance energy trans-
fer, an approach that does not depend on the detergent ex-
traction of the TCR, indicating that at least two  /  het-
erodimers are present in the complex (16). However, the
coexistence of monovalent with bivalent and multivalent
TCRs was not excluded. This study allows us to conclude
that monovalent and multivalent TCR complexes exist si-
multaneously in the plasma membrane of unstimulated T
cells (Fig. 6 A). This conclusion is supported by a previous
report showing a decrease but not a complete abrogation of
MHCp tetramer binding in T cells treated with M CD,
suggesting that two different TCR populations might exist
on the surface of living cells (31).
It has already been pointed out that a bivalent/multiva-
lent TCR might improve the high off rate found for mono-
valent MHCp binding and can resolve the paradox of the high
specificity–low affinity TCR–MHCp interaction (32). How-
ever, this does not readily explain how T cells manage to re-
spond to a wide range of MHCp concentrations (6, 23–25).
The coexistence of monovalent and multivalent TCRs may
clarify this issue. Theoretical calculations suggest that cells co-
expressing monovalent and multivalent forms of a given re-
ceptor can show high sensitivity to low concentrations of a
ligand and concentration-dependent responses to high ligand
concentrations (33). Indeed, by analyzing antigen-stimulated
TCRs in BN-PAGE, we show that the multivalent TCR
might facilitate signaling at low MHCp doses because only
these complexes are phosphorylated at low peptide concen-
trations. On the other hand, the monovalent TCRs are only
phosphorylated at high concentrations of peptide antigen, a
situation in which the multivalent TCRs might already be
saturated. Thus, the presence of monovalent TCRs might
endow the T cell with the capacity to produce a concentra-
tion-dependent response even at high MHCp doses. In con-
trast, the multivalent complexes may augment the sensitivity
of the T cell to antigen simply by increasing the avidity for an
MHCp dimer or, additionally, by spreading the signal (i.e.,
the ligand-induced signaling activity of one receptor propa-
gates to neighboring receptors of the same multimer),
thereby amplifying the effect of binding. This spreading of
activity could be accomplished by cooperative interactions
between the different receptors (Fig. 6 B) or by very low af-
finity binding of MHC/self-peptides to the neighboring re-
ceptors (Fig. 6 B; references 34, 41). With respect to the mo-
lecular mechanisms that might propagate the triggering signal
from engaged to nonengaged TCRs, one could hypothesize
that the linear arrangement of the multivalent TCRs could
serve to transmit the signal along the multimer axis as a
“domino effect.” Recently, spread of activity from engaged
to nonengaged receptors within an oligomer has been de-
scribed for bacterial chemotaxis receptors (34). Alternatively,
the linear arrays of multivalent complexes could help to seri-
ally trigger several TCRs by a single MHCp (35).
The existence of multivalent TCRs could also shed light
on how the receptor transmits signals across the membrane.
On antigen binding, the TCR undergoes a conformational
change that makes the proline-rich sequence of the CD3 
tail more accessible to binding of the Nck adaptor (3, 8).
Crystallography of the soluble part of the  /  heterodimer
Figure 6. A model of TCR signaling via mono- and multivalent 
complexes can account for high sensitivity and wide response range 
of T cells to antigen. (A) Multivalent and monovalent TCR complexes 
coexist on the surface of nonstimulated T cells. For simplicity, a single TCR 
complex is depicted as a ligand-binding ectodomain (corresponding to the 
TCR /  heterodimer) and signal-transducing cytoplasmic tails (represent-
ing the CD3 subunits). (B) At low MHCp concentrations, the multimeric 
complexes become preferentially phosphorylated. This might be caused by 
their higher avidity for dimeric MHC/agonistic peptide (blue, MHCp molecules). 
On ligand binding, the triggering signal might propagate to neighboring 
TCRs of the same multimer by a spreading of the conformational change 
via cooperative interactions and by the spreading of tyrosine phosphorylation 
(red, tails of activated CD3). Alternatively, the TCR /  heterodimers of a 
multivalent TCR that are not engaged by MHC/agonistic peptide might 
bind to MHC/self-peptide (B , green). By amplifying the effect of a few 
MHCp binding events to neighboring receptors within a TCR multimer, the 
T cell might be able to respond to very low MHCp doses. (C) At higher 
MHCp concentrations, the monovalent TCRs begin to be phosphorylated, 
indicating that they now also bind to MHCp, which dimerizes or clusters 
the monovalent TCRs. This allows the T cell to sense high doses of antigen, 
a situation in which the multivalent TCRs are already saturated.JEM VOL. 202, August 15, 2005 501
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alone or together with MHCp demonstrated that, with one
exception (9), the  /  ectodomains do not change their
structure appreciably on antigen binding, making it difficult
to imagine how a change in conformation could be induced
in the CD3 subunits (10, 11). However, in the multivalent
complexes, the simultaneous binding of both  / s to
MHCp could alter the distance or the orientation of one of
the  /  heterodimers with respect to the other (36, 37)
without changing the structure of either individual  /  unit
(Fig. 6). This could lead to a rearrangement of the whole
TCR complex, including its cytoplasmic tails. Indeed, it has
been shown that, at the cell surface, MHC class I and II are
present as dimers or in even larger arrays (38–40). Thus, in
principle, two identical agonist peptides could simulta-
neously bind to one multivalent TCR complex or, alter-
natively, one agonist peptide could bind together with a
self-peptide to the second MHC molecule (41, 42). Such a
scenario would also explain why, unlike dimeric MHCp,
monomeric soluble MHCp does not activate T cells, pro-
viding an alternate explanation to the proposed need for
TCR clustering (4–6).
Lipid rafts are thought to be cholesterol-rich micro-
domains in the plasma membrane. We show that the extrac-
tion of cholesterol disrupts the multivalent TCR complexes
but leaves the monovalent complexes intact. This finding
suggests that cholesterol molecules might contribute to the
TCR multimers and that these multimers might assemble
raft-like structures around them. In agreement with this
idea, several reports have proposed that part of the TCR is
present in lipid rafts in nonstimulated T cells (29, 43).
Monovalent complexes seem not to depend on cholesterol
and, thus, they might be located in a different lipid environ-
ment than the multivalent complexes, opening the possibil-
ity that both receptor forms could couple to different signal-
ing molecules. Cholesterol extraction of T cells impairs
TCR-induced signaling, suggesting that lipid rafts are im-
portant for the transduction of signals via the TCR (44–46).
This finding can now be reinterpreted in the light of the
deleterious effect of cholesterol depletion on the integrity of
multivalent TCR complexes.
Our findings are also in line with others that demonstrate
the effect of cholesterol on soluble MHCp binding to T
cells. Flow cytometry studies have shown that the avidity of
MHCp tetramer binding to T cells diminishes after choles-
terol extraction without reducing the number of TCR mol-
ecules (31, 47, 48). Because cholesterol depletion disrupts
multivalent TCRs, the picture that emerges is that these
TCRs would be responsible for high-avidity MHCp tet-
ramer-binding, whereas the monovalent TCR independent
of cholesterol binds MHCp tetramers with lower avidity.
Furthermore, a cholesterol-dependent increase in TCR
avidity for MHCp tetramers has been shown in activated
versus naive T cells (47). We suggest that T cells might regu-
late their sensitivity to antigen recognition by altering the ra-
tio of monovalent to multivalent TCRs, although this re-
mains to be demonstrated.
MATERIALS AND METHODS
Expression vector. The plasmid pSR -scTCRV 3 encoding the
scTCRV 3 fusion protein has been described previously (8). In brief, the
NP-specific sc containing the fused variable Ig domains of the light and
heavy chain of an NP-specific antibody was fused to the NH2 terminus of a
mature TCR  protein to yield the chimera scTCR .
Cells. The Jk.scTCR  cell line (clone 2D10) was obtained by transfecting
Jk cells with the pSR -scTCRV 3 expression vector. The transfectants 31-
13.scTCR  and Jk.flag  have been described previously (8). scTCR  re-
constituted the expression of the TCR complex in the TCR -deficient
mutant (unpublished data), showing that the chimera assembles into the
complete TCR complex. The Jk HA1.7 TCR -TCR  transfectant
(CH7C17) was a gift from A. Alcover (Institut Pasteur, Paris, France) and
the B cell line J558L m3-11 was a gift from M. Reth (Max-Planck-Institut
für Immunbiologie, Freiburg, Germany). The murine citochrome c–respon-
sive T cell hybridoma 2B4 was provided by J. Ashwell (National Cancer In-
stitute, Bethesda, MD). Fibroblast cell lines DAP DR1 , stably transfected
with HLA class II DR1 and ICAM-1 molecules, and DCEK, stably trans-
fected with IEk and CD80 expression vectors, were provided by M. Owen
(Cancer Research UK, London, UK) and R. Germain (National Institutes
of Health, Bethesda, MD), respectively. Human PBMCs were isolated from
healthy donors using a Ficoll gradient. All cells were maintained in com-
plete RPMI 1640 with 5% FBS.
Antibodies and reagents. The rabbit anti-  antiserum 448 has been de-
scribed previously (8). The following TCR antibodies were used: 17-34-14
(anti–human V 8; G. Spagnoli, University of Basel, Basel, Switzerland),
RP221 (anti-CD45; F. Sánchez-Madrid, Hospital de la Princesa, Madrid,
Spain), Jovi1 (C 1) and Jovi3 (V 3; M. Owen), UCHT1 (anti-CD3; P.
Beverly, The Edward Jenner Institute for Vaccine Research, Berkshire,
UK), and MEM-43/5 (anti-CD59) and anti-Lck antibodies (V. Horejsi, In-
stitute of Molecular Genetics, Prague, Czech Republic). The antiphospho-
tyrosine (4G10) and anti-LAT antibodies were purchased from Upstate
Biotechnology, the anti-Flag (M2) was purchased from Sigma-Aldrich, the
anti-CD3 OKT3 hybridoma was purchased from the American Type Cul-
ture Collection, and the anti-CD69–PE was purchased from Caltag. Fab
fragments were prepared using the Immunopure IgG1 Fab Preparation Kit
(Pierce Chemical Co.) and confirmed by SDS-PAGE and silver staining.
Secondary antibodies were obtained from Southern Biotechnology Associ-
ates, Inc. NP-conjugated Sepharose and NIP-conjugated Sepharose, as well
as free NIP (NIPcap), were purchased from Biosearch Technologies.
M CD was obtained from Sigma-Aldrich.
TCR purifications. The scTCR was purified from cell lysates using NP-
conjugated Sepharose that was washed three times, and the scTCR was eluted
in BN buffer containing the appropriate detergent and 0.5 mM free NIP. Al-
ternatively, membrane fractions were prepared by disrupting 107 cells in 1 ml
of a hypotonic buffer (10 mM Hepes, pH7.4, 42 mM KCl, 5 mM MgCl2, and
protease inhibitors) using a Dounce homogenizer and pelleting the membranes
in an ultracentrifuge (Sorvall; Combi) at 150,000 g. Membranes were lysed in
150  l BN buffer containing the appropriate detergent. The third method
used to isolate TCR involved incubating 107 cells in 200  M pervanadate (8.8
 l of 23 mM sodium orthovanadate plus 1.2  l of 30% H2O2) at 37 C for 5
min in 1 ml RPMI 1640. Cells were lysed in 1 ml of lysis buffer containing 20
mM TrisHCl, pH 8, 137 mM NaCl, 2 mM EDTA, 10% glycerol, 10  g/ml
leupeptin, 10  g/ml aprotinin, 1 mM PMSF, 500  M sodium orthovanadate,
1 mM NaF, and the appropriate detergent (1% digitonin or 0.5% Brij96 unless
otherwise indicated). Phosphorylated proteins were purified with 1  g 4G10
and 3  l protein G–Sepharose, washed three times, and subsequently eluted in
BN buffer (500 mM  -aminocaproic acid, 20 mM NaCl, 10% glycerol, 2 mM
EDTA, and 20 mM BisTris, pH 7.0), including 50 mM phenylphosphate, 1
unit alkaline phosphatase, and the appropriate detergent.
For peptide antigen stimulation, DAP-DR1 cells were loaded overnight
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1640 with 1% FCS, as indicated in the figures. Cells were removed from the
dish with 0.5 mM EDTA and washed twice in PBS. CH7C17 (or Jk) cells
were starved overnight in RPMI 1640 without FCS. For each stimulation,
2.5   107 T cells were mixed with 2   107 APCs, centrifuged briefly, and
maintained as a pellet for 5 min at 37 C before lysis in the lysis buffer men-
tioned above containing 0.5% Brij96. After affinity purification with an-
tiphosphotyrosine antibodies, proteins were eluted as above, with the addition
of sodium orthovanadate, and in the absence of phosphatases. For stimulation
of 2B4 cells, DCEK (15   107 per point) was loaded for 2 h with the PCC
peptide KAERADLIAYLKQATK in RPMI 1640 without serum. 2B4 cells
(50   107 per point) were mixed with the antigen-loaded DCEK and stimu-
lated as for CH7C17 cells. Anti-CD3 (UCHT1) immunoprecipitations were
performed as described above for the antiphosphotyrosine purification.
Antibody shift assay, BN-PAGE, and SDS-PAGE. The antibody or
Fab fragment amounts indicated were added to the samples (15 to 20  l)
and incubated for 30 min on ice before BN-PAGE loading. When  2  l of
antibody had to be added (because of low antibody concentrations), the an-
tibody was dialyzed against BN buffer to prevent introducing an excess of
NaCl. Samples were separated by BN-PAGE (5.5–15%) at 4 C as previ-
ously described (19, 49). Ferritin was used as the marker protein in its 24-
mer, 48-mer, and 72-mer forms (f1, 440 kD; f2, 880 kD; and f3, 1,320 kD).
SDS-PAGE and Western blotting were performed using standard protocols.
Immunogold detection of surface TCR by label fracture and elec-
tron microscopy. 2B4 cells, untreated or treated with 5 mM M CD at
37 C for 30 min in RPMI 1640 were fixed with ice-cold 2% paraformalde-
hyde in PBS for 30 min at 0 C and washed with RPMI 1640. Cells were
incubated with 20  g/ml 145-2C11 or H57-597 antibodies for 30 min at
0 C, followed by 10 nm gold-conjugated protein A (vol/vol, 1:100; Sigma-
Aldrich). Samples were adsorbed on mica sheets pretreated with 100  g/ml
polylysine and kept at 0 C for 90 min. After washing, 0.1% (wt/vol) glu-
taraldehyde was added for 20 min. The samples were processed for label
fracture and metal replication as described previously (50). A sandwich was
made with another mica sheet, fast frozen in liquid ethane (104  C/s), and
transferred into a freeze fracture unit (BAF 060; BAL-TEC). Etching was
performed for 15 min after switching temperatures from –150 to –90 C.
Metal replicas of the exposed surfaces were obtained by evaporating 2 nm of
platinum with an electron gun at an angle of 45  and 20 nm of carbon with
an electron gun at an angle of 90 . Replicas were floated in commercial
bleach and incubated overnight for the digestion of cellular material. After
washing, replicas were picked up in uncoated copper electron microscopy
grids and examined in a transmission electron microscope (1200-EX II;
JEOL) operating at 100 kV. Individual and groups of gold particles were
counted in 20 cells per sample. Human PBMCs and CH7C17 cells were
prepared for label fracture and electron microscopy as above, except that
OKT3 was used for T cell staining after fixation in paraformaldehyde.
CD69 up-regulation and surface iodination. 105  DAP-DR1 or
DCEK APCs were incubated overnight with the concentrations of the
HA307-319 peptide indicated in the figures. To stimulate the CH7C17 T
cell line, the supernatant of the DAP-DR1 cells was removed and 105
CH7C17 cells were added for 24 h at 37 C. Cells were stained with PE-
labeled anti-CD69 antibodies (1:100), washed, and analyzed with a FACS-
Calibur (Becton Dickinson). Surface iodination was performed using the
lactoperoxidase method as described previously (51).
Online supplemental material. Fig. S1 shows a two-dimensional BN/
SDS-PAGE electrophoresis of TCR isolated from flag CD3 -transfected Jk
cells immunoblotted with anti-TCR , anti-flag, and anti-  antibodies. Fig.
S2 shows a gel shift assay on TCR isolated from 2B4 cells and incubated
with different doses of a Fab fragment of anti-TCR  antibody H57-597.
Fig. S3 shows a BN-PAGE of TCR extracted from 2B4 and Jk cells with
the limiting concentrations of Brij96. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20042155/DC1.
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